MTD Healthcare

Mettler-Toledo International Inc.

$1,698.04+1.18%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Diagnostics & Research
Country: Switzerland
Market cap: 34.0B USD
Enterprise value: 34.6B USD
Full-time employees: 16,600

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.22 vs a peer median of 0.63), less short-term liquidity (current ratio 1.12 vs a peer median of 2.59) and more debt relative to equity (164.70× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.22 vs peers 0.63), less liquidity (current ratio 1.12 vs peers 2.59) and more debt vs equity (164.70× vs peers 0.22×)
About average: growth and valuation

Ranks #646 of 1,157 healthcare companies (bottom 45%)

See how it ranks against its peers

Worth knowing

Much more borrowing than peers. Debt is 164.7× equity vs a peer median of 0.2×.Debt is 164.7× equity vs peers 0.2×.
Debt is 164.7× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 164.7× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.
Profit is backed by cash. Free cash flow is 95% of reported profit.
Mettler-Toledo International's free cash flow is 95% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.
Wide margins. Operating margin 26% (12 months to Jun 2026) vs a peer median of 7.1%.Operating margin 26% vs peers 7.1%.
Mettler-Toledo International keeps 26% of revenue as operating profit, more than 90% of peers (median 7.1%).

StockQuotient Score

49/ 100

Oct 5 50 → Nov 4 49 (-1)

Valuation

Is the price right?

51/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield2.7%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 0.80Sector median: 0.0148 · MAD: 0.0148

EBITDA yield3.2%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score -0.20Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield2.5%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield0.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

45/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Held back by:

▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth12.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.08Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth1.5%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.52Sector median: 0.0584 · MAD: 0.0840

Revenue growth6.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.08Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

97/100

Strong

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ ROA
▲ ROIC
▲ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin26.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.57Sector median: 0.0706 · MAD: 0.1217

Return on assets24.7%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital41.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 3.64Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin60.3%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity7062.4%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.22

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.76Sector median: 0.6250 · MAD: 0.3380

Current ratio1.12×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.06Sector median: 2.5860 · MAD: 1.3850

Debt / equity164.70×

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentile33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Mettler-Toledo International

Is Mettler-Toledo International getting weaker?: Its latest SEC filing (Jul 31, 2026) showed no major changes. Its overall score is unchanged at 49/100 since Oct 28, 2026.
How is Mettler-Toledo International valued vs its peers?: Priced about in line with its peers. Valuation scores 51/100 against 1,393 healthcare peers.
Is Mettler-Toledo International growing?: At about the same pace as its peers. Growth scores 45/100 against 1,393 healthcare peers. 3-year revenue growth 1.5% vs a peer median of 5.8% (weaker than 67% of peers).3-year revenue growth 1.5% vs peers 5.8% (weaker than 67% of peers).
How profitable is Mettler-Toledo International?: More profitable than most of its peers. Profitability scores 97/100 against 1,393 healthcare peers. Return on assets 24.7% vs a peer median of 1.7% (stronger than 95% of peers).Return on assets 24.7% vs peers 1.7% (stronger than 95% of peers).
How risky is Mettler-Toledo International?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 164.70× vs a peer median of 0.22× (weaker than 100% of peers).Debt / equity 164.70× vs peers 0.22× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 31, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	4.1B USD	4.1B USD	+1.1%
Net income (12 months)	875.1M USD	905.6M USD	+3.5%
Operating margin	25.3%	26.2%	+0.9 pts
Free cash flow (12 months)	793.8M USD	864.0M USD	+8.8%
Debt	2.2B USD	2.1B USD	−5.2%
Cash	60.6M USD	51.4M USD	−15.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	58.4%	58.9%	59.2%	60.1%	59.4%	▼ 0.7 pts
Operating margin	25.5%	27.1%	25.6%	26.7%	25.6%	▼ 1.0 pts
Net margin	20.7%	22.3%	20.8%	22.3%	21.6%	▼ 0.7 pts
Return on assets (ROA)	23.1%	25.0%	23.5%	26.6%	23.4%	▼ 3.2 pts
Return on equity (ROE)	448.6%	—	—	—	—	—
Free cash flow margin	21.6%	18.8%	22.7%	22.3%	21.1%	▼ 1.2 pts
Current ratio	1.11×	1.20×	1.04×	1.02×	1.14×	▲ 11%
Quick ratio	0.75×	0.81×	0.71×	0.73×	0.81×	▲ 12%
Debt to equity	9.81×	—	—	—	—	—
Interest coverage	21.88×	19.16×	12.53×	13.84×	15.06×	▲ 8.9%

MTD price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.22 vs a peer median of 0.63), less short-term liquidity (current ratio 1.12 vs a peer median of 2.59) and more debt relative to equity (164.70× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.22 vs peers 0.63), less liquidity (current ratio 1.12 vs peers 2.59) and more debt vs equity (164.70× vs peers 0.22×)

About average: growth and valuation

Ranks #646 of 1,157 healthcare companies (bottom 45%)

See how it ranks against its peers

Worth knowing

Much more borrowing than peers. Debt is 164.7× equity vs a peer median of 0.2×.Debt is 164.7× equity vs peers 0.2×.

Debt is 164.7× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 164.7× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.

Profit is backed by cash. Free cash flow is 95% of reported profit.

Mettler-Toledo International's free cash flow is 95% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Wide margins. Operating margin 26% (12 months to Jun 2026) vs a peer median of 7.1%.Operating margin 26% vs peers 7.1%.

Mettler-Toledo International keeps 26% of revenue as operating profit, more than 90% of peers (median 7.1%).

Questions investors ask about Mettler-Toledo International

Is Mettler-Toledo International getting weaker?

Its latest SEC filing (Jul 31, 2026) showed no major changes. Its overall score is unchanged at 49/100 since Oct 28, 2026.

How is Mettler-Toledo International valued vs its peers?

Priced about in line with its peers. Valuation scores 51/100 against 1,393 healthcare peers.

Is Mettler-Toledo International growing?

At about the same pace as its peers. Growth scores 45/100 against 1,393 healthcare peers. 3-year revenue growth 1.5% vs a peer median of 5.8% (weaker than 67% of peers).3-year revenue growth 1.5% vs peers 5.8% (weaker than 67% of peers).

How profitable is Mettler-Toledo International?

More profitable than most of its peers. Profitability scores 97/100 against 1,393 healthcare peers. Return on assets 24.7% vs a peer median of 1.7% (stronger than 95% of peers).Return on assets 24.7% vs peers 1.7% (stronger than 95% of peers).

How risky is Mettler-Toledo International?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 164.70× vs a peer median of 0.22× (weaker than 100% of peers).Debt / equity 164.70× vs peers 0.22× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

4.1B USD

4.1B USD

+1.1%

Net income (12 months)

875.1M USD

905.6M USD

+3.5%

Operating margin

25.3%

26.2%

+0.9 pts

Free cash flow (12 months)

793.8M USD

864.0M USD

+8.8%

Debt

2.2B USD

2.1B USD

−5.2%

Cash

60.6M USD

51.4M USD

−15.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

58.4%

58.9%

59.2%

60.1%

59.4%

▼ 0.7 pts

Operating margin

25.5%

27.1%

25.6%

26.7%

25.6%

▼ 1.0 pts

Net margin

20.7%

22.3%

20.8%

22.3%

21.6%

▼ 0.7 pts

Return on assets (ROA)

23.1%

25.0%

23.5%

26.6%

23.4%

▼ 3.2 pts

Return on equity (ROE)

448.6%

—

Free cash flow margin

21.6%

18.8%

22.7%

22.3%

21.1%

▼ 1.2 pts

Current ratio

1.11×

1.20×

1.04×

1.02×

1.14×

▲ 11%

Quick ratio

0.75×

0.81×

0.71×

0.73×

0.81×

▲ 12%

Debt to equity

9.81×

—

Interest coverage

21.88×

19.16×

12.53×

13.84×

15.06×

▲ 8.9%